Semaglutide Improves Heart Filling in Obesity-Linked Heart Failure
A substudy of the CAMEO-SEMA trial links the drug to better left atrial and ventricular function in patients with preserved ejection fraction.
Updated on Nov. 8, 2026 in Heart Disease
A cardiac magnetic resonance substudy of the randomized CAMEO-SEMA trial found semaglutide improved left atrial reservoir strain and left ventricular filling in obesity-related heart failure with preserved ejection fraction. The substudy enrolled 49 participants, 33 receiving semaglutide and 16 receiving placebo, and imaging was repeated at 52 weeks.
Why it matters
Heart failure with preserved ejection fraction is difficult to treat, and these findings suggest semaglutide may act on cardiac filling mechanics, not only weight. The associations with lower exercise pulmonary artery wedge pressure link the imaging changes to a measure of pressure in the lungs during exertion.
The substudy was prespecified and enrolled 49 participants, including 28 women, with imaging at baseline and 52 weeks. Correlations between improved atrial strain and reduced exercise pulmonary artery wedge pressure (r=-0.46) and between improved ventricular filling and the same pressure measure (r=-0.65) were observed, but the study's size limits how firmly these links can be generalized.
The players
CAMEO-SEMA trial
A randomized clinical trial evaluating semaglutide in patients with obesity-related heart failure with preserved ejection fraction, of which this cardiac imaging study is a prespecified substudy.
The details
Semaglutide also reduced left ventricular mass and improved right ventricular function and biventricular myocardial mechanics in the substudy. Researchers performed cardiac magnetic resonance within one day of invasive exercise hemodynamic assessment, linking imaging changes to direct pressure measurements.
Timeline
Baseline: initial cardiac magnetic resonance imaging of participants.
52 weeks: follow-up cardiac magnetic resonance imaging after treatment.
Health Landscape
The findings extend the CAMEO-SEMA randomized trial by moving from clinical outcomes to imaging of cardiac filling mechanics in heart failure with preserved ejection fraction. Because this condition has few proven therapies, evidence that semaglutide improves atrial and ventricular function adds to the growing investigation of incretin-based drugs in cardiovascular care.
For people living with heart failure with preserved ejection fraction, these findings suggest semaglutide may influence how the heart fills and how pressure builds during exertion. Any change in treatment would depend on larger trials confirming benefit and safety before clinical use.
The takeaway
Weight-loss drugs may affect heart mechanics beyond body weight, but the evidence here comes from a small imaging substudy. Patients should discuss any heart failure treatment decisions with their clinicians.
Further reading
For more on treatments for heart conditions, explore our Heart Disease coverage.
Source note: This article includes information reported by Nature.
